This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.

Para mayor información puede contactarse a ó 0800-345-NOVO (6686)




Material entregado a profesionales de la salud AR23ESP00021




Esperoct® - Especialidad Medicinal autorizada por el Ministerio de Salud. Certificado N° 59.382. Prospecto vigente aprobado por Disposición DI-2021-1038-APN-ANMAT#MS (05-Feb-2021)


Giangrande P, Andreeva T, Chowdary P, ct al. Clinical evafu.:ition of glycoPEGytated recombinant FVIII: efficacy .:ind safety in severe haemophilia A. Thromb Hoemosr. 2017; 117(02):252-261.



Cafuir Land Kempton C. Currem and emerging factor vm replacement products for hemophilia A. Ther Adv Hem. 2017;8(10):303-313.



Lentz SR. Kavalki K. Ktamroth R. et al. Turoccocog alpha pegol (NB~GP) in severe hemophilia A:. long-term safety and efficacy in previously tr e.:i ted patients of all ages in the pathfinder8 study. Res Proct Thromb Haemosc 2022:6(2):e 12674.



National Hemophilia Foundation. MASAC recommendations concerning prophylaxis~ #241. New York, NY: National Hemophilia Foundation; 2016.



Adynovate00 [p.:ickagc insert]. Westlake Village. CA: Baxter Healthcare Corpor ation; 2021. 8. Jivi" (package insert]. Whippany, NJ: Bayer HealthCare LLC: 2018.



Jivi" (package insert]. Whippany, NJ: Bayer HealthCare LLC: 2018.